rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors.
|
25629371 |
2015 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We retrospectively evaluated the clinical effects and safety profiles of second-line cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with NSCLC harboring sensitive EGFR mutations (exon 19 deletion/exon 21 L858R mutation).
|
29737372 |
2018 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
|
30471829 |
2018 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
L858R point mutation is the most common oncogenic mutation in EGFR tyrosine kinase domain in patients with EGFR-mutated NSCLC.
|
31116768 |
2019 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
First- and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the evidence-based first-line treatment for metastatic non-small-cell lung cancers (NSCLCs) that harbor sensitizing EGFR mutations (i.e. exon 19 deletions or L858R).
|
26943236 |
2016 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis.
|
25222496 |
2014 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The in vivo antitumor efficacy study demonstrated that compound 3x significantly inhibited tumor growth and induced tumor stasis in an EGFR-T790M/L858R-driven human nonsmall-cell lung cancer xenograft mouse model.
|
24053674 |
2013 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In particular, a number of EGFR mutants that demonstrate ligand-independent signaling are common in non-small cell lung cancer (NSCLC), including kinase domain mutations L858R (also called L834R) and exon 19 deletions (e.g., ΔL747-P753insS), which collectively make up nearly 90% of mutations in NSCLC.
|
26337388 |
2015 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Isolated metastasis of an EGFR-L858R-mutated NSCLC of the meninges: the potential impact of CXCL12/CXCR4 axis in EGFR<sub>mut</sub> NSCLC in diagnosis, follow-up and treatment.
|
29721166 |
2018 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Although most EGFR mutations detected are short deletions in exon 19 or the L858R point mutation in exon 21, more than 75 different EGFR kinase domain residues have been reported to be altered in NSCLC patients.
|
17877814 |
2007 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Multiple randomized clinical trials have demonstrated that epidermal growth factor receptor (EGFR) exon 19 deletion (19Del) and exon 21 L858R mutation (L858R) are highly correlated with sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment in non-small-cell lung cancer (NSCLC).
|
29581983 |
2018 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Eight patients received an EGFR TKI: three cases with G719X plus another mutation had partial responses (PRs) to erlotinib; of three cases with L858R plus another mutation, two displayed PRs and one (with EGFR-L858R+A871G) progressive disease (PD) to erlotinib; one NSCLC with EGFR-L861Q+E709A and one with delL747_T751+R776S had PRs to EGFR TKIs.
|
23242437 |
2013 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A total of 116 patients with completely resected II-IIIA NSCLC and confirmed positive EGFR mutation (exon 19 deletion or exon 21 Leu858Arg) between January 2013 and March 2017 were included in our study.
|
30369426 |
2018 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In the phase III FLAURA study, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib significantly improved progression-free survival (PFS) versus standard-of-care (SoC) EGFR-TKI (gefitinib or erlotinib) in patients with previously untreated EGFR (exon 19 deletion or L858R) mutation-positive advanced non-small cell lung cancer (NSCLC).
|
30659024 |
2019 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
HRMA is a precise method for detecting DEL and L858R mutations and is useful for predicting clinical outcomes in patients with advanced NSCLC treated with gefitinib.
|
17875767 |
2007 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The results suggest that low gefitinib plasma concentrations in patients with exon 21 L858R point mutations may be associated with shorter PFS in NSCLC patients.
|
28391354 |
2017 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The trial was conducted in 17 US academic and community medical centers among 88 patients with EGFR exon 19 deletion or exon 21 L858R mutation based on local testing and stage 4 NSCLC who were eligible for bevacizumab.
|
31393548 |
2019 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
AS-PCR analysis of treatment-naïve tumor samples revealed somatic T790M mutation in 3/394 (1%) non-small cell lung carcinomas (NSCLC) carrying the tyrosine kinase inhibitor (TKI)-sensitizing EGFR mutation, but in none of 334 NSCLC lacking EGFR exon 19 deletions (ex19del) or L858R substitutions and in none of 235 non-lung tumors.
|
30145586 |
2018 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Common epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC) predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs), with exon 19 deletions being associated with better outcome compared to L858R mutations.
|
30473385 |
2019 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
This study was conducted to compare the efficacy of a combination of icotinib and chemotherapy with icotinib or chemotherapy alone in untreated non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR)-sensitive mutations and to analyze the curative effect of different treatments on different genetic mutations (EGFR 19 exon deletion and L858R mutation) in a real-life setting.
|
29731642 |
2018 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In non-small cell lung cancer (NSCLC), the association between common EGFR mutations (Del EX19/L858R) with EGFR tyrosine kinase inhibitors (EGFR-TKIs) has been well established.
|
25558790 |
2015 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
It is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 19 deletions or exon 21 (L858R) mutations.
|
24844234 |
2014 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Non-small cell lung cancer (NSCLC) patients carrying specific EGFR kinase activating mutations (L858R, delE746-A750) respond well to tyrosine kinase inhibitors (TKIs).
|
27612423 |
2016 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Exon 19 deletion mutations and the single-point substitution mutation L858R in exon 21 are the most frequent in NSCLC and are termed 'classical' mutations.
|
19680293 |
2009 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Non-small cell lung cancer (NSCLC) with minor mutations in the epidermal growth factor receptor (EGFR) gene, except for the common 15 base-pair deletions in exon 19 and the L858R mutation in exon 21, is rare, and only few data exist on this patient population.
|
26124334 |
2015 |